title: [A 17-year study of bloodstream Escherichia coli infection after liver transplantation: resistance rate, risk factor and mortality].
abstract: OBJECTIVE
  To explore the resistance rate, risk factors and mortality of Escherichia coli bloodstream infections (BSI) after liver transplantation.
  
  
  METHODS
  From January 1993 to May 2010, a retrospective analysis of Escherichia coli in liver transplants were conducted.
  
  
  RESULTS
  A total of 88 BSI occurred in 83/695 patients and Escherichia coli (n = 23) was most commonly found. Carbapenem and piperacillin-tazobactam were the most consistently active against Escherichia coli while the resistance rate to enterococcus for ciprofloxacin, gentamycin, ampicillin-clavulanic acid was over 60%. Univariate analysis identified the following variables as risk factors for Escherichia coli bacteremia: cholangioenterostomy (P < 0.001) and ductal complications (P < 0.001). Escherichia coli bloodstream infection could increase the mortality at 15 days after bloodstream infection. No significant difference in mortality occurred at 30 days and 1 year after enterococcal bacteremia.
  
  
  CONCLUSIONS
  Escherichia coli after liver transplantation is resistant to agents but commonly active to carbapenem and piperacillin-tazobactam. The risk factor associated with Escherichia coli bloodstream infections are cholangioenterostomy and ductal complications. Escherichia coli bloodstream infection can increase the mortality at 15 days after bloodstream infection.
authors.affiliation: Organ Transplantation Center, First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Tai
authors.forename: Xiao-shun
authors.initials: XS
authors.lastname: He
authors.forename: An-bin
authors.initials: AB
authors.lastname: Hu
authors.forename: Lin-wei
authors.initials: LW
authors.lastname: Wu
authors.forename: Wei-qiang
authors.initials: WQ
authors.lastname: Ju
authors.forename: Xiao-feng
authors.initials: XF
authors.lastname: Zhu
authors.forename: Dong-ping
authors.initials: DP
authors.lastname: Wang
authors.forename: Guo-dong
authors.initials: GD
authors.lastname: Wang
authors.forename: Yi
authors.initials: Y
authors.lastname: Ma
authors.forename: Zhi-yong
authors.initials: ZY
authors.lastname: Guo
authors.forename: Jie-fu
authors.initials: JF
authors.lastname: Huang
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016470:Bacteremia / Q000209:etiology / Q000401:mortality*; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects*; D004927:Escherichia coli Infections / Q000209:etiology / Q000401:mortality*; D005260:Female; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate
chemical_list: D000900:Anti-Bacterial Agents